Correlation of mutant menin stability with clinical expression of multiple endocrine neoplasia type 1 and its incomplete forms

Cancer Science

Volumn 102, Issue 11, 2011, Pages 2097-2102

  Shimazu, Satoko ^a   Nagamura, Yuko ^a   Yaguchi, Hiroko ^b   Ohkura, Naganari ^c   Tsukada, Toshihiko ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

METHIONINE; MUTANT PROTEIN; PROTEASOME; TRANSCRIPTION FACTOR JUND; UBIQUITIN;

ARTICLE; CONTROLLED STUDY; DELETION MUTANT; ENDOCRINE DISEASE; FAMILIAL ISOLATED HYPERPARATHYROIDISM; GENE DELETION; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; GERM LINE; HUMAN; HUMAN CELL; MEN1 GENE; MISSENSE MUTATION; MULTIPLE ENDOCRINE NEOPLASIA; NONSENSE MUTATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN STABILITY; SPORADIC PARATHYROID TUMOR; TRANSACTIVATION; TUMOR SUPPRESSOR GENE; WILD TYPE;

AMINO ACID SUBSTITUTION; ANIMALS; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; CODON, NONSENSE; COS CELLS; GENETIC HETEROGENEITY; GENOTYPE; GERM-LINE MUTATION; HUMANS; HYPERPARATHYROIDISM, PRIMARY; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1; MUTATION; MUTATION, MISSENSE; PARATHYROID NEOPLASMS; PHENOTYPE; POINT MUTATION; PROTEIN STABILITY; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-JUN; RECOMBINANT FUSION PROTEINS; SEQUENCE DELETION; TRANSCRIPTIONAL ACTIVATION;

EID: 80054992134     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.02055.x     Document Type: Article

References (40)

1. Chandrasekharappa SC, Guru SC, Manickam P et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 1997; 276: 404-7.
2. Tsukada T, Nagamura Y, Ohkura N. MEN1 gene and its mutations: basic and clinical implications. Cancer Sci 2009; 100: 209-15.
3. Guru SC, Goldsmith PK, Burns AL et al. Menin, the product of the MEN1 gene, is a nuclear protein. Proc Natl Acad Sci USA 1998; 95: 1630-4.
4. Agarwal SK, Guru SC, Heppner C et al. Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription. Cell 1999; 96: 143-52.
5. Yokoyama A, Cleary ML. Menin critically links MLL proteins with LEDGF on cancer-associated target genes. Cancer Cell 2008; 14: 36-46.
6. Tsukada T, Yamaguchi K, Kameya T. The MEN1 gene and associated diseases: an update. Endocr Pathol 2001; 12: 259-73.
7. Lemos MC, Thakker RV. Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene. Hum Mutat 2008; 29: 22-32.
8. Shimizu S, Tsukada T, Futami H et al. Germline mutations of the MEN1 gene in Japanese kindred with multiple endocrine neoplasia type 1. Jpn J Cancer Res 1997; 88: 1029-32.
9. Fujimori M, Shirahama S, Sakurai A et al. Novel V184E MEN1 germline mutation in a Japanese kindred with familial hyperparathyroidism. Am J Med Genet 1998; 80: 221-2.
10. Teh BT, Esapa CT, Houlston R et al. A family with isolated hyperparathyroidism segregating a missense MEN1 mutation and showing loss of the wild-type alleles in the parathyroid tumors. Am J Hum Genet 1998; 63: 1544-9.
11. Uchino S, Noguchi S, Sato M et al. Screening of the MEN1 gene and discovery of germ-line and somatic mutations in apparently sporadic parathyroid tumors. Cancer Res 2000; 60: 5553-7.
12. Honda M, Tsukada T, Tanaka H et al. A novel mutation of the MEN1 gene in a Japanese kindred with familial isolated primary hyperparathyroidism. Eur J Endocrinol 2000; 142: 138-43.
13. Wautot V, Vercherat C, Lespinasse J et al. Germline mutation profile of MEN1 in multiple endocrine neoplasia type 1: search for correlation between phenotype and the functional domains of the MEN1 protein. Hum Mutat 2002; 20: 35-47.
14. Yaguchi H, Ohkura N, Takahashi M, Nagamura Y, Kitabayashi I, Tsukada T. Menin missense mutants associated with multiple endocrine neoplasia type 1 are rapidly degraded via the ubiquitin-proteasome pathway. Mol Cell Biol 2004; 24: 6569-80.
15. Maruyama K, Tsukada T, Hosono T et al. Structure and distribution of rat menin mRNA. Mol Cell Endocrinol 1999; 156: 25-33.
16. Agarwal SK, Kester MB, Debelenko LV et al. Germline mutations of the MEN1 gene in familial multiple endocrine neoplasia type 1 and related states. Hum Mol Genet 1997; 6: 1169-75.
17. Balogh K, Hunyady L, Patocs A et al. MEN1 gene mutations in Hungarian patients with multiple endocrine neoplasia type 1. Clin Endocrinol (Oxf) 2007; 67: 727-34.
18. Pannett AAJ, Kennedy AM, Tuner JJO et al. Multiple endocrine neoplasia type 1 (MEN1) germline mutations in familial isolated primary hyperparathyroidism. Clin Endocrinol (Oxf) 2003; 58: 639-46.
19. Tham E, Grandell U, Lindgren E, Toss G, Skogseid B, Nordenskjöld M. Clinical testing for mutations in the MEN1 gene in Sweden: a report on 200 unrelated cases. J Clin Endocrinol Metab 2007; 92: 3389-95.
20. Teh BT, Kytölä S, Farnebo F et al. Mutation analysis of the MEN1 gene in multiple endocrine neoplasia type 1, familial acromegaly and familial isolated hyperparathyroidism. J Clin Endocrinol Metab 1998; 83: 2621-6.
21. Jäger AC, Friis-Hansen L, Hansen TV et al. Characteristics of the Danish families with multiple endocrine neoplasia type 1. Mol Cell Endocrinol 2006; 249: 123-32.
22. Warner J, Epstein M, Sweet A et al. Genetic testing in familial isolated hyperparathyroidism: unexpected results and their implications. J Med Genet 2004; 41: 155-60.
23. Hannan FM, Nesbit MA, Christie PT et al. Familial isolated primary hyperparathyroidism caused by mutations of the MEN1 gene. Nat Clin Pract Endocrinol Metab 2008; 4: 53-8.
24. Cardinal JW, Bergman L, Hayward N et al. A report of a national mutation testing service for the MEN1 gene: clinical presentations and implications for mutation testing. J Med Genet 2005; 42: 69-74.
25. Kassem M, Kruse TA, Wong FK, Larsson C, Teh BT. Familial isolated hyperparathyroidism as a variant of multiple endocrine neoplasia type 1 in a large Danish pedigree. J Clin Endocrinol Metab 2000; 85: 165-7.
26. Poncin J, Abs R, Velkeniers B et al. Mutation analysis of the MEN1 gene in Belgian patients with multiple endocrine neoplasia type 1 and related diseases. Hum Mutat 1999; 13: 54-60.
27. Perrier ND, Villablanca A, Larsson C et al. Genetic screening for MEN1 mutations in families presenting with familial primary hyperparathyroidism. World J Surg 2002; 26: 907-13.
28. Klein RD, Salih S, Bessoni J, Bale AE. Clinical testing for multiple endocrine neoplasia type 1 in a DNA diagnostic laboratory. Genet Med 2005; 7: 131-8.
29. Tanaka C, Yoshimoto K, Yamada S et al. Absence of germ-line mutations of the multiple endocrine neoplasia type 1 (MEN1) gene in familial pituitary adenoma in contrast to MEN1 in Japanese. J Clin Endocrinol Metab 1998; 83: 960-5.
30. Sato M, Matsubara S, Miyauchi A et al. Identification of five novel germline mutations of MEN1 gene in Japanese multiple endocrine neoplasia type 1 (MEN1) families. J Med Genet 1998; 35: 915-9.
31. Giraud S, Zhang CX, Serova-Sinilnikova O et al. Germ-line mutation analysis in patients with multiple endocrine neoplasia type 1 and related disorders. Am J Hum Genet 1998; 63: 455-67.
32. Ohkura N, Nagamura Y, Tsukada T. Differential transactivation by orphan nuclear receptor NOR1 and its fusion gene product EWS/NOR1: possible involvement of poly(ADP-ribose) polymerase I, PARP-1. J Cell Biochem 2008; 105: 785-800.
33. Stewart C, Parente F, Piehl F et al. Characterization of the mouse Men1 gene and its expression during development. Oncogene 1998; 17: 2485-93.
34. Lemos MC, Harding B, Reed AAC et al. Genetic background influences embryonic lethality and the occurrence of neural tube defects in Men1 null mice: relevance to genetic modifiers. J Endocrinol 2009; 203: 133-42.
35. Brandi ML, Gagel RF, Angeli A et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001; 86: 5658-71.
36. Maruyama K, Tsukada T, Honda M et al. Complementary DNA structure and genomic organization of Drosophila menin. Mol Cell Endocrinol 2000; 168: 135-40.
37. Schoenfeld AR, Davidowitz EJ, Burk RD. Elongin BC complex prevents degradation of von Hippel-Lindau tumor suppressor gene products. Proc Natl Acad Sci USA 2000; 97: 8507-12.
38. Giovannini M, Robanus-Maandag E, Niwa-Kawakita M et al. Schwann cell hyperplasia and tumors in transgenic mice expressing a naturally occurring mutant NF2 protein. Genes Dev 1999; 13: 978-86.
39. Gautreau A, Manent J, Fievet B, Louvard D, Giovannini M, Arpin M. Mutant products of the NF2 tumor suppressor gene are degraded by the ubiquitin-proteasome pathway. J Biol Chem 2002; 277: 31279-82.
40. Crabtree JS, Scacheri PC, Ward JM et al. A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors. Proc Natl Acad Sci USA 2001; 98: 1118-23.